These countermeasures should also include therapeutic drugs for HF with new mechanisms of action, which will also be commercially available in Japan, such as ivabradine [22], sacubitril/valsartan [23], omecamtiv mecarbil [24], and sodium-glucose cotransporter 2 (SGLT2) inhibitors [25]. This evidence concerns the gene SLC5A2 and hydrops fetalis.